- Trials with a EudraCT protocol (829)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
829 result(s) found for: covid-19.
Displaying page 6 of 42.
| EudraCT Number: 2021-000930-32 | Sponsor Protocol Number: SJ2021005 | Start Date*: 2021-04-27 |
| Sponsor Name:AZ Sint-Jan Brugge-Oostende AV | ||
| Full Title: COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 | ||
| Medical condition: hemodialysis patients hemodialysis patients with comorbidities | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001327-13 | Sponsor Protocol Number: OnCoVID19Trial | Start Date*: 2020-04-21 |
| Sponsor Name:Med. Univ. Wien | ||
| Full Title: A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVI... | ||
| Medical condition: Cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-005094-28 | Sponsor Protocol Number: VAC3_COVID-19_antibody_study_V1 | Start Date*: 2021-10-21 |
| Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
| Full Title: Population-based prospective, clinical study on efficacy and safety of a booster COVID-19 vaccination | ||
| Medical condition: SARS-CoV-2 infection prevention | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-002233-15 | Sponsor Protocol Number: NICCAM-001 | Start Date*: 2020-06-17 | |||||||||||
| Sponsor Name:Charité Research Organisation GmbH | |||||||||||||
| Full Title: A randomized, single blind, placebo-controlled, multiple dose, parallel-arm study to investigate the safety and preliminary efficacy of the combination of Niclosamide and Camostat to treat COVID-19... | |||||||||||||
| Medical condition: SARS-Coronavirus 2 disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-000300-38 | Sponsor Protocol Number: 001610 | Start Date*: 2021-02-05 |
| Sponsor Name:Antwerp University Hospital | ||
| Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE) | ||
| Medical condition: Onco-hematological patients | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2022-001097-64 | Sponsor Protocol Number: CVD19-ESCIN | Start Date*: 2022-07-14 | |||||||||||
| Sponsor Name:UAB Švenčionių vaistažolės | |||||||||||||
| Full Title: An open-label, randomized, parallel-controlled, phase II clinical trial to evaluate the tolerability, efficacy and safety of Aesculus Hippocastanum L seed extract in COVID-19 patients with mild pne... | |||||||||||||
| Medical condition: COVID-19 patients with mild pneumonia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: LT (Prohibited by CA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002448-21 | Sponsor Protocol Number: ACTIVATEII | Start Date*: 2020-05-26 | ||||||||||||||||
| Sponsor Name:Hellenic Institute for the Study of Sepsis | ||||||||||||||||||
| Full Title: A RANDOMIZED CLINICAL TRIAL FOR ENHANCED TRAINED IMMUNE RESPONSES THROUGH BACILLUS CALMETTE-GUÉRIN VACCINATION TO PREVENT INFECTIONS ΒΥ COVID-19: THE ACTIVATE II TRIAL | ||||||||||||||||||
| Medical condition: Prevention of COVID-19 infection | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2022-002378-95 | Sponsor Protocol Number: D7000C00001 | Start Date*: 2023-06-21 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase I/III Randomized, Double-blind Study to Evaluate the Safety, Efficacy, and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions ... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) SE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-001338-21 | Sponsor Protocol Number: I4V-MC-KHAB | Start Date*: 2021-11-04 | |||||||||||
| Sponsor Name:Lilly S.A. | |||||||||||||
| Full Title: A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients from 1 Year to Less Than 18 Years Old Hospitalized with COVID-19 | |||||||||||||
| Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001655-13 | Sponsor Protocol Number: NL2021-8172 | Start Date*: 2021-04-01 |
| Sponsor Name:Radboudumc | ||
| Full Title: SARS-CoV2 vaccination and activation of the coagulation system | ||
| Medical condition: Coronavirus disease 2019 and thromboembolism | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-001200-42 | Sponsor Protocol Number: CamoCO-19-001 | Start Date*: 2020-03-30 | |||||||||||
| Sponsor Name:Department of Infecitous Diseases, Aarhus University Hospital | |||||||||||||
| Full Title: The Impact of Camostat Mesilate on COVID-19 Infection: An investigator-initiated randomized, placebo-controlled, phase IIa trial | |||||||||||||
| Medical condition: 2019-nCoV acute respiratory disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Prematurely Ended) SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-002211-21 | Sponsor Protocol Number: SGS.1656.201 | Start Date*: 2020-07-31 | |||||||||||
| Sponsor Name:St George Street Capital Ltd | |||||||||||||
| Full Title: A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA... | |||||||||||||
| Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-005486-14 | Sponsor Protocol Number: EPIC-19 | Start Date*: 2021-01-11 |
| Sponsor Name:Wroclaw Medical University | ||
| Full Title: Using of convalescent plasma in the treatment of COVID-19 patients with metabolomic and laboratory evaluation of the progress of plasma therapy | ||
| Medical condition: Covid-19 (Coronavirus Disease 2019) – acute infectious disease of the respiratory system caused by SARS-CoV-2 infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: PL (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-001040-10 | Sponsor Protocol Number: CoVVac | Start Date*: 2021-04-26 | |||||||||||
| Sponsor Name:Medical University of Graz | |||||||||||||
| Full Title: Humoral and cellular immune response to COVID-19 vaccines in immunocompromised and healthy individuals – The CoVVac study | |||||||||||||
| Medical condition: Active immunisation to prevent COVID-19 in immunocompromised individuals. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004259-17 | Sponsor Protocol Number: NS3.1 | Start Date*: 2022-03-02 | |||||||||||
| Sponsor Name:OBCTCD-24 Ltd | |||||||||||||
| Full Title: A Phase IIb Randomized, Quadruple-blinded Multicenter, Multinational, Placebo-controlled Study to Evaluate the safety and efficacy of exosomes overexpressing CD24 to prevent clinical deterioration ... | |||||||||||||
| Medical condition: COVID-19 disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-002542-16 | Sponsor Protocol Number: INSIGHT013 | Start Date*: 2020-09-30 | |||||||||||
| Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota | |||||||||||||
| Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the... | |||||||||||||
| Medical condition: COVID-19 (SARS-CoV-2) infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
| Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
| Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
| Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-004571-41 | Sponsor Protocol Number: RBMinCovid19 | Start Date*: 2021-02-23 | |||||||||||
| Sponsor Name:Cyxone AB | |||||||||||||
| Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19) | |||||||||||||
| Medical condition: Coronavirus Disease (COVID-19) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-003277-55 | Sponsor Protocol Number: CAR-CF | Start Date*: 2021-09-01 | ||||||||||||||||
| Sponsor Name:Medical University of Innsbruck, University Clinic for Pediatrics III | ||||||||||||||||||
| Full Title: COVID-19 Antibody Responses in Cystic Fibrosis: CAR-CF | ||||||||||||||||||
| Medical condition: COVID-19 vaccine Antibody response from natural infection or after vaccination in patients with Cystic Fibrosis (CF) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: AT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-003125-39 | Sponsor Protocol Number: TRI-08892 | Start Date*: 2020-10-12 |
| Sponsor Name:Thrombosis Research Institute | ||
| Full Title: Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap... | ||
| Medical condition: Confirmed diagnosis of SARS-CoV-2 with symptomatic COVID-19 infection | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.